Skip to main content

paxalisib

paxalisib: 6 clinical trials tracked.

paxalisib evidence translation

What we can confirm

6 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about paxalisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (6)

5G-PEARL: Paxalisib in Combination With Temozolomide in Patients With High Grade Malignant Brain Tumours Within the 5G Platform

NCT07391215Registry updated 2026-02-05·Phase 1/Phase 2
Recruiting

Primary endpoint: Phase 1b - Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in patients with malignant brain tumours

Interventionalopen64 targetStarted 2026-01Completion 2029-061 site · United KingdomInstitute of Cancer Research, United Kingdom

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

NCT06208657Registry updated 2026-01-28·Phase 1/Phase 2
Recruiting

Primary endpoint: Number of participants treated with molecularly-targeted agents in each treatment arm.

Interventionalopen90 targetStarted 2024-07Completion 2035-1214 sites · Australia, CanadaAustralian & New Zealand Children's Haematology/Oncology Group

A Phase 2 Trial of Paxalisib Combined With a Ketogenic Diet and Metformin for Newly Diagnosed and Recurrent Glioblastoma

NCT05183204Registry updated 2026-09-25·Phase 2
Completed

Primary endpoint: Progression-free survival, defined as the survival rate at 6 months

Interventionalopen24 enrolledStarted 2022-02Completion 2026-081 site · United StatesWeill Medical College of Cornell University

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

NCT05009992Registry updated 2026-06-26·Phase 2
Recruiting

Primary endpoint: Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B Only

InterventionalRandomizedopen360 targetStarted 2021-10Completion 2029-0632 sites · Australia, Israel, Netherlands, New Zealand…University of California, San Francisco

A Phase 2 Study of Paxalisib (GDC-0084) in Recurrent or Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT04906096Registry updated 2026-08-05·Phase 2
Recruiting

Primary endpoint: Number of participants with Objective Response Rate (ORR)

Interventionalopen25 targetStarted 2021-06Completion 2027-122 sites · United StatesLakshmi Nayak, MD

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

NCT03970447Registry updated 2026-10-01·Phase 2/Phase 3
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen2,250 targetStarted 2019-07Completion 2030-0663 sites · Australia, Canada, France, Germany…Global Coalition for Adaptive Research